

Flash Report
*-FY09 Financial Performance &
FY10 Outlook-*

Teijin Limited
May 10, 2010


(1) Consolidated Results Highlights

(¥bn)

Full-Term Operating Movement



Quarterly Movement



◆ Operating Results

(¥bn)	FY08	FY09	Diff. Amount	FY09 4Q
Net sales	943.4	765.8	-177.6	205.6
OP	18.0	13.4	-4.5	2.1
OP margin	1.9%	1.8%	-0.2%	1.0%
Nonoperating items (net)	-20.6	-11.4	+9.3	-2.1
Ordinary income	-2.7	2.1	+4.8	-0.1
Extraordinary items(net)	-31.2	-38.7	-7.5	0.3
Income before income taxes	-33.9	-36.6	-2.7	0.3
Income taxes	10.2	-1.5	-11.8	4.0
Minority interest of consolidated subsidiaries(net)	-1.2	0.6	+1.8	0.5
Net income	-43.0	-35.7	+7.3	-4.2
EPS (¥)	-43.65	-36.26	+7.39	

- Steady progress was made in the implementation of urgent measures and structural reforms
- Significant restructuring costs led to a second consecutive full-term net loss
- Returned to profitability at the ordinary income level, thanks to an improvement in net nonoperating expenses
- Free cash flow improved substantially, owing to restraints on capital investment and the reduction of inventories

Year-end dividend: ¥2.0/share; annual dividend: ¥2.0/share

EBITDA*	85.3	75.3	-10.0
CAPEX	75.8	36.3	-39.5
Depreciation & amortization	67.4	61.9	-5.5
R&D expenses	37.6	33.4	-4.3
FCF	-75.9	47.0	+122.9

*EBITDA = Operating income + Depreciation & amortization

◆ PL exchange rate

	FY08 Average	FY09 Average
¥/US\$	103	94
¥/€	152	130
US\$/€	1.47	1.39

Note: Fiscal year-end for overseas companies is Dec 31.

◆ Extraordinary items

	FY08	FY09			Diff.
		1Q-3Q	4Q	total	
(¥bn)					
Gain on sales of property, plant and equipment	1.3	1.0	0.0	1.0	-0.3
Gain on sales of investment securities	0.2	1.5	5.8	7.2	+7.0
Others	0.6	0.4	0.9	1.2	+0.6
Extraordinary income total	2.1	2.9	6.6	9.5	+7.4
Special factory operating loss	10.2	9.3	1.4	10.7	+0.5
Loss on impairment	11.6	2.9	1.5	4.4	-7.2
Restructuring costs	3.3	19.4	1.2	20.6	+17.3
Additional contribution to reserve to cover losses on disposal of securities with market value held in money trusts	-	7.2	-	7.2	+7.2
Others	8.2	3.0	2.2	5.2	-3.0
Extraordinary losses total	33.3	41.9	6.3	48.2	+14.8
Extraordinary items total	-31.2	-39.0	0.3	-38.7	-7.5

➤ Extraordinary items:

Net decline of ¥7.5 billion

▪ Positive factors:

Increase in gain on sales of investment securities; decline in loss on impairment

▪ Negative factors:

Restructuring costs (related to the transfer of stake in Indonesian fibers subsidiary); loss owing to additional contribution to reserve to cover losses on disposal of securities with market value held in money trusts

➤ Income taxes: Down ¥11.8 billion

Income taxes	10.2	-5.5	4.0	-1.5	-11.8
Minority interest in net losses of consolidated subsidiaries	-1.2	0.1	0.5	0.6	+1.8

◆ Financial Position

(¥bn)	Mar. 31, '09	Mar. 31, '10	Diff.	(Impact of foreign exchange rate)
Total assets	874.2	823.1	-51.1	2.8
Shareholders' equity	305.6	271.3	-34.3	2.3
Interest-bearing debt	361.3	320.3	-41.1	2.0

D/E ratio	1.18	1.18	-0.0
Shareholders' equity ratio	35.0%	33.0%	-2.0%
BPS (¥)	310.49	276.24	-34.25

- Total assets: Down
 - owing to reduction of inventories, restraints on capital investment and the advance of depreciation and amortization
- Shareholders' equity: Down
 - owing to net loss
- Interest-bearing debt: Down
 - reflecting declines in inventories and capital investment

◆ Cash Flows





(¥bn)	Operating activities	Investing activities	FCF	Financing activities	Cash & cash equivalents
FY09	80.4	-33.4	47.0	-42.9	4.1
FY08	40.4	-116.3	-75.9	77.2	1.3

◇ BS exchange rate

	Dec. 31, '08	Dec. 31, '09
¥/US\$	91	92
¥/€	128	132
US\$/€	1.41	1.43

Note: Fiscal year-end for overseas companies is Dec 31.

◆ Analysis of Changes in Operating Results and Financial Position




◆ Reduce Fixed Costs, Freeze Major Capital Investment for Two Years and Increase the Efficiency of Working Capital

■ Reduction of Fixed Costs


Down by ¥34.0 billion in FY09

(¥bn)




■ Free Cash Flow

(¥bn)




■ Capital Investment/Depreciation and Amortization

(¥bn)



■ Inventories

(¥bn)




* 4Q inventory turnover is calculated based on cost of sales for the full term.

(2) Operating Results by Segment (Comparison with FY08)


(¥bn)	Sales				OP			
	FY08	FY09	Diff.	% Change	FY08	FY09	Diff.	% Change
Synthetic Fibers	273.2	205.2	-68.1	-24.9%	-2.8	-15.1	-12.3	-
Films & Plastics	258.0	177.8	-80.2	-31.1%	0.2	8.0	+7.8	-
Pharma. & H.H.C.	127.1	131.7	+4.6	+3.6%	24.8	24.2	-0.6	-2.6%
Trading & Retail	239.2	205.3	-33.8	-14.2%	3.9	3.4	-0.4	-11.2%
IT and New Products etc.	45.9	45.9	-0.0	-0.0%	3.6	3.0	-0.6	-17.7%
Elimination & corporate	-	-	-	-	-11.8	-10.0	+1.7	-
Total	943.4	765.8	-177.6	-18.8%	18.0	13.4	-4.5	-25.2%

◆ Sales

◇ Materials businesses




◇ Nonmaterials businesses




◆ OP

◇ Materials businesses




◇ Nonmaterials businesses



* Materials businesses : Synthetic fibers, Films & Plastics
Nonmaterials businesses : Pharma. & H.H.C., Trading & Retail, IT & New Products, etc.

① Synthetic Fibers: Decline in sales, significant operating loss

◆ Summary & Actions



◇ Aramid Fibers:

- Para-aramid fibers: Demand for use in automotive-related materials revived
- Meta-aramid fibers: Sales for use in industrial materials picked up

◇ Carbon Fibers:

- First half: Sluggish for general industrial applications and sports & leisure equipment
- Second half: Production adjustments in the aircraft industry were an issue


◇ Polyester Fibers:

- Domestic sales for use in textiles stagnated
- Sales for use in industrial materials appeared to be on the road to recovery, particularly for automotive applications

◆ Operating Results (compared with FY08)

Aramid Fibers	Decline in sales and operating income	Production and shipments down sharply
Carbon Fibers	Decline in sales; significant operating loss	Production and shipments down sharply
Polyester Fibers	Decline in sales; operating loss shrank	Efforts to reduce costs narrowed operating loss

② Films and Plastics: Decline in sales, sharp increase in operating income



◆ Summary & Actions

◇ Plastics :

- Polycarbonate resin: Demand was brisk, bolstered by demand in the PRC
- Processed polycarbonate resin products: Sales of transparent electroconductive film and retardation film were robust

◇ Films :

- PET film (Japan): Demand rallied, particularly in Asia; shipments picked up for optical applications, notably flat panel displays (FPDs)
- PET film (Europe & USA): Proceeded with structural reforms


◆ Operating Results (compared with FY08)

Plastics	Decline in sales, increase in operating income	Efforts to reduce costs supported an increase in operating income
Films	Decline in sales and operating income	Sales declined steeply, owing to transformation of U.S. subsidiary into an equity-method affiliate, among others; operating income fell, attributable to a decline in shipments and others


③ Pharmaceuticals & Home Health Care: Increase in sales, operating income edged down

◆ Summary & Actions

Sales



OP



◇ Pharmaceuticals:

- Sales of Bonalon 35mg tablet increased favorably
- TMX-67*1:
 - Sales in the United States rose steadily
 - The Menarini Group began marketing in Europe (March 2010)
 - Application filed in Japan on December 25, 2009
- ITM-077*2, NTC-801*3: Entered phase II clinical trials(April 2010)

◇ Home Health Care:

- HOT: Rental volume remained high
- CPAP/SAFHS: Rental volume rose favorably

◆ Operating Results (compared with FY08)


Pharmaceuticals and Home Health Care	Increase in sales, decline in operating income	Shipments increased, technology licensing fees declined
--------------------------------------	--	---

*1 Treatment for gout and hyperuricemia

*2 Treatment for type II diabetes

*3 Treatment for atrial fibrillation and flutter

④ Trading & Retail: Decline in sales and operating income



◆ Summary & Actions

◇ Trading & Retail


- **Textiles & Apparel**
 - Sales of both raw yarn and fabrics fell
 - Promote efforts to expand new businesses, including opening a new store operated by I.T.'S International Co., Ltd., a joint venture specialty retailer of private-label apparel
- **Industrial Textiles & Materials**
 - Sales of automotive-related materials revived
 - Sales of products for interior applications were favorable
 - General-purpose materials continued to struggle

◆ Operating Results (compared with FY08)

Trading & Retail	Decline in sales and operating income	Shipments fell
------------------	---------------------------------------	----------------

⑤ IT & New Products, etc.: Sales level, operating income down

◆ Summary & Actions



◇ IT:

- Measures to enhance profitability were promoted in both the IT solutions and Services businesses

◇ New Products, etc.:

- Bioplastics:
 - Developed a new antihydrolysis technology for *BIOFRONT* (June 2009)
 - Brought new demonstration plant for *BIOFRONT* on line (September 2009)
- Basic R&D:
 - Inaugurated the Integrative Technology Research Institute* (July 2009)

*Purpose: R&D aimed at developing new technologies for biopolymers, advanced medical materials and electronics materials, as well as in fields that integrate such technologies.

◆ Operating Results (compared with FY08)


IT	Increase in sales and operating income	Shipments increased and costs were reduced
----	--	--

(3) Changes in Operating Income by Geographical Segment

FY08
 FY09
 (¥bn)


Japan

Operating income was up for plastics and pharmaceuticals & home health care; operating loss shrank for polyester fibers; operating income was down for films




Asia

Operating loss narrowed for polyester fibers; operating income increased for plastics




Americas

Operating income declined for carbon fibers, aramid fibers and pharmaceuticals & home health care; amortization of goodwill increased



Europe





Operating income was down sharply for aramid fibers and down for carbon fibers







(4) Changes in Operating Income by Business Segment

Sales

FY08 FY09 (¥bn)



OP




(5) Overview of Main Subsidiaries of Poorly Performing Businesses

Sales

● FY08 ■ FY09


(¥bn)

◆ Teijin Fibers & Three fibers companies in Southeast Asia




*1 Figures for Teijin Fibers include the results of newly consolidated TS Aromatics Limited, a JV with Showa Shell Sekiyu K.K.

◆ Films business group






*2 Net sales and operating income of our U.S. joint venture have been excluded from consolidated results since the first quarter of fiscal 2009.

◆ Plastics business group



OP



(1) Summary of Outlook for FY10

(¥bn)	FY09	FY10	Difference	
			Amount	%
Net sales	765.8	800.0	+34.2	+4.5%
Operating income	13.4	32.0	+18.6	+138.2%
Operating margin	1.8%	4.0%	+2.2%	-
Ordinary income	2.1	26.0	+23.9	-
Net income	-35.7	10.0	+45.7	-

EBITDA	75.3	92.0	+16.7
CAPEX	36.3	35.0	-1.3
Depreciation & amortization	61.9	60.0	-1.9
R&D expenses	33.4	32.0	-1.4
FCF	47.0	20.0	-27.0

(¥bn)	Mar. 31, '10	Mar. 31, '11	Difference
Assets:			
Inventories	106.3	110.0	+3.7
Total	823.1	810.0	-13.1
Interest-bearing debt	320.3	300.0	-20.3

Note: EBITDA = (Operating income + Depreciation & amortization)

◆ Dividends Declared for Fiscal 2009 and Forecast for Fiscal 2010 (Yen/share)

Interim	-	2.0	+2.0
Year-end	2.0	2.0	0
Annual dividends	2.0	4.0	+2.0

(2) Outlook by Segment

		FY09			FY10 Outlook			Diff. (Y to Y)
		1H	2H	Total	1H	2H	Total	
Net Sales	(¥bn)							
	High-Performance Fibers	37.3	45.8	83.1	55.0	60.0	115.0	+31.9
	Polyester Fibers	60.2	61.9	122.1	50.0	50.0	100.0	-22.1
	Films & Plastics	80.2	97.6	177.8	95.0	105.0	200.0	+22.2
	Pharma. & H.H.C.	65.0	66.7	131.7	65.0	70.0	135.0	+3.3
	Trading & Retail	96.1	109.2	205.3	100.0	110.0	210.0	+4.7
	IT & Others	21.3	24.5	45.9	20.0	20.0	40.0	-5.9
Total		360.2	405.6	765.8	385.0	415.0	800.0	+34.2
Operating Income	High-Performance Fibers	-4.6	-3.8	-8.4	0.0	1.0	1.0	+9.4
	Polyester Fibers	-2.7	-4.0	-6.7	-0.5	0.5	0.0	+6.7
	Films & Plastics	0.5	7.5	8.0	6.0	8.0	14.0	+6.0
	Pharma. & H.H.C.	12.5	11.7	24.2	11.0	12.0	23.0	-1.2
	Trading & Retail	1.0	2.4	3.4	1.0	3.0	4.0	+0.6
	IT & Others	0.8	2.1	3.0	0.5	2.5	3.0	+0.0
	Elimination & corporate	-4.8	-5.3	-10.0	-6.0	-7.0	-13.0	-3.0
Total		2.8	10.7	13.4	12.0	20.0	32.0	+18.6

Note: In line with changes to the Accounting Standard for Disclosures about Segments of an Enterprise and Related Information, effective from fiscal 2010 Teijin has divided its former Synthetic Fibers segment into the "High-Performance Fibers" and "Polyester Fibers" segments. Teijin has also renamed its IT and New Products, etc., segment "IT and Others." Coinciding with this, Teijin reassessed the standards it uses to determine the apportioning of shared costs included in elimination and corporate. Application of the revised standards in fiscal 2009 would have increased the charge for elimination and corporate by ¥2.7 billion.

(3) Financial Highlights

	FY06 Actual	FY07 Actual	FY08 Actual	FY09 Actual	FY10 Outlook
ROA * ¹	7.7%	6.5%	1.9%	1.6%	4.0%
ROE * ²	9.7%	3.3%	-12.3%	-12.4%	3.6%
Operating margin	7.4%	6.3%	1.9%	1.8%	4.0%
D/E ratio	0.81	0.83	1.18	1.18	1.1
Shareholders' equity ratio	36.7%	38.5%	35.0%	33.0%	34%
Total asset turnover	1.04	1.03	1.00	0.90	0.98
Earnings per share (¥)	36.8	13.2	-43.7	-36.3	10.2
Dividends per share (¥)	10.0	8.0	5.0	2.0	4.0
Total assets (¥bn)	999.9	1,016.0	874.2	823.1	810.0
Interest-bearing debt (¥bn)	295.5	325.2	361.3	320.3	310.0
EBITDA (¥bn) * ³	129.1	127.8	85.3	75.3	92.0

*1. ROA= Operating income/Total assets

*2. ROE= Net income/Shareholders' equity

*3. EBITDA = Operating income + Depreciation & amortization

Disclaimer Regarding Forward-Looking Statements and Business Risks

Disclaimer

Any statements in this document, other than those of historical fact, are forward-looking statements about the future performance of Teijin and its Group companies, which are based on management's assumptions and beliefs in light of information currently available, and involve risks and uncertainties. Actual results may differ materially from these forecasts.

Business Risks

The Teijin Group recognizes certain risks as having the potential to affect its operating results and/or financial position. As of the date of this document, these risks included, but were not limited to, the risks listed below. Despite the current upheaval in the global financial markets, the Teijin Group faces very little risk of a widening of spreads on funds procured in foreign currencies and is not in a position that would make it difficult to procure necessary funds. With the impact of the financial crisis having spread to the real economy, however, there is a risk in the Group's materials businesses that shipments will continue to dwindle as demand abates.

(1) Market-related risk

The Teijin Group manufactures and sells products, the sales of which may be affected by market conditions, competition with other companies and price fluctuations arising thereof, as well as fluctuations in raw materials prices and fuel costs, and such market factors as fluctuations in foreign exchange and interest rates.

(2) Product quality risk

Teijin's pharmaceuticals and home health care businesses manufacture and sell products that may affect the lives of users. Accordingly, quality issues relating to such products have the potential to negatively affect, among others, the Group's operating results, financial position and public reputation.


(3) R&D-related risk in the pharmaceuticals business

R&D in the pharmaceuticals business is characterized by significant investments of funds and time. Pharmaceuticals discovery research has a high incidence of failure to discover promising drugs. There are also risks that plans to apply for regulatory approval may be abandoned or that approval may be rescinded.


This material is based on the consolidated results for FY09 announced at 11:30 A.M. on May 10, 2010 (local time in Japan).

All product names in this document are registered trademarks.


◆ Yen/Dollar, Yen/Euro Exchange Rates



◆ Dollar/Euro Exchange Rates




◆ Polyester Fibers Prices, Raw Materials Prices



【Source: Teijin estimates based on data published by PCI】

◆ Domestic Production of Carbon Fibers



【Source: Ceramic statistics published by Ministry of Economy, Trade and Industry】

◆ Supply capacity for PAN-based carbon fibers (partially estimated)

<Tons>

	2006	2007	2008	2009	2010
Toho Tenax Co., Ltd (Japan)	3,700	3,700	6,400	6,400	6,400
Toho Tenax America, Inc (U.S)	2,000	2,000	2,000	2,400	2,400
Toho Tenax Europe (Germany)	3,400	3,400	3,400	5,100	5,100
Toho Group total	9,100	9,100	11,800	13,900	13,900
Other manufactures	31,050	42,650	51,000	59,350	67,250
PAN-based carbon fiber total	40,150	51,750	62,800	73,250	81,150
Change (%)	18	29	21	17	11

*Production capacity is based on year-end figures.

◆ Supply capacity for Oxidized PAN Fiber

<Tons>

Toho Group total	2,000	2,000	2,000	2,000	2,000
-------------------------	--------------	--------------	--------------	--------------	--------------

◆ Demand forecast for PAN-based carbon fibers (outlook by application)





<Tons>

	2007	2008	2009	2010	2011	2012	2013	2014
Aerospace	6,140	6,410	4,310	5,250	7,280	9,040	10,260	12,030
Recreation	8,090	5,660	5,210	5,600	7,800	8,060	7,890	8,140
Industrial	16,850	15,210	13,940	17,220	20,100	23,840	29,300	33,830
Total	31,080	27,280	23,460	28,070	35,180	40,940	47,450	54,000
Change (%)	17	-12	-14	20	25	16	16	14

<Source:Toho Tenax>


Average Operating Rates at Production Facilities in Materials Businesses and Regional Operating Rates in Poorly Performing Businesses

◆ Asia ■ Japan




◆ CAPEX, Depreciation & Amortization, and R&D Expenses


CAPEX/Depreciation & Amortization



R&D Expenses



◆ Movement of Results



ROA(%)	6.5	1.9	1.6	4.0
ROE(%)	3.3	-12.3	-12.4	3.6
Operating margin (%)	6.3	1.9	1.8	4.0
D/E ratio	0.83	1.18	1.18	1.1

Note: ROA = OP / Total assets

◆ Strategies and Actions by Business Segment

	Strategies and Actions
High-Performance Fibers	<ul style="list-style-type: none"> • Aramid fibers: Promote decisive efforts to develop new products and applications; reduce costs and inventories • Carbon fibers: Strengthen sales capabilities, positioning us well to cultivate demand and bolster sales; pare fixed costs; create an efficient production system
Polyester Fibers	<ul style="list-style-type: none"> • Create an optimal global production configuration, thereby facilitating the reduction of costs; achieve a return to profitability by reinforcing efforts in downstream businesses
Films and Plastics	<ul style="list-style-type: none"> • Plastics: Reinforce our operating foundation in the PRC; expand our processed plastics business • Films: Respond to increasing demand, particularly for thick films; press ahead with the restructuring of our plants in Europe and the United States
Pharmaceuticals and Home Health Care	<ul style="list-style-type: none"> • Increase sales of pharmaceuticals and rentals of home health care equipment • Expand sales of TMX-67 in Europe and the United States; strengthen profitability of overseas home health care operations
Trading and Retail	<ul style="list-style-type: none"> • Maximize our global network and cultivate commercial rights in promising sectors
IT and Others	<ul style="list-style-type: none"> • IT: Establish a profitable business structure that is not easily swayed by market fluctuations
New Business Development	<ul style="list-style-type: none"> • Work to achieve the early commercialization of new products in key businesses and strengthen development capabilities

◆ Consolidated Statements of Income

	FY08		FY09		Diff.	
	Amount	% of total	Amount	% of total	Amount	%
(¥bn)						
Net Sales	943.4	100.0%	765.8	100.0%	-177.6	-18.8%
Cost of sales	724.8	76.8%	573.9	74.9%	-150.8	-20.8%
Gross profit	218.6	23.2%	191.9	25.1%	-26.7	-12.2%
SG & A	200.7	21.3%	178.5	23.3%	-22.2	-11.1%
Operating income	18.0	1.9%	13.4	1.8%	-4.5	-25.2%
Nonoperating items (net)	-20.6	-	-11.4	-	+9.3	-
(Balance of financial expenses)	-8.7	-	-4.2	-	+4.6	-
(Equity on gains and losses of unconsolidated subsidiaries and affiliates)	-8.0	-	-3.4	-	-4.7	-
Ordinary income	-2.7	-	2.1	0.3%	+4.8	-
Extraordinary items(net)	-31.2	-	-38.7	-	-7.5	-
Income before income taxes	-33.9	-	-36.6	-	-2.7	-
Income taxes	10.2	1.1%	-1.5	-	-11.8	-
Minority interest (net)	-1.2	-	0.6	0.1%	+1.8	-
Net income	-43.0	-	-35.7	-	+7.3	-

Note: For more information, see the Financial Statements-Summary for the year ended March 31, 2010.

◆ Consolidated Balance Sheets <Assets>

	(¥bn)	Mar 31, 2009	Mar 31, 2010	Diff.	
				Amount	%
Total assets		874.2	823.1	-51.1	-5.8%
Current assets		351.1	332.7	-18.4	-5.2%
Cash and time deposits		19.0	23.1	+4.2	+22.0%
Trade notes and accounts receivable		151.9	159.0	+7.0	+4.6%
Inventories		135.1	106.3	-28.8	-21.3%
Others		45.2	44.4	-0.8	-1.8%
Fixed assets		523.0	490.3	-32.7	-6.3%
Tangible assets		339.7	316.9	-22.8	-6.7%
Intangible assets		82.0	77.4	-4.5	-5.5%
Investments and other assets		101.4	96.0	-5.4	-5.3%

Note: For more information, see the Financial Statements-Summary for the year ended March 31, 2010.

◆ Consolidated Balance Sheets <Liabilities and net assets>

	(¥bn)	Mar 31, 2009	Mar 31, 2010	Diff.	
				Amount	%
Total liabilities and net assets		874.2	823.1	-51.1	-5.8%
Liabilities		544.2	527.8	-16.4	-3.0%
Current liabilities		325.1	293.8	-31.2	-9.6%
Noncurrent liabilities		219.1	233.9	+14.8	+6.8%
(Interest-bearing debt)		361.3	320.3	-41.1	-11.4%
Net assets		330.0	295.3	-3.47	-10.5%
Shareholders' equity		322.8	284.4	-38.4	-11.9%
Valuation and translation adjustments and others		-17.2	-13.0	+4.2	-
Stock acquisition rights		0.3	0.4	+0.1	+25.1%
Minority interests in consolidated subsidiaries		24.1	23.6	-0.5	-2.1%

Note: For more information, see the Financial Statements-Summary for the year ended March 31, 2010.

◆ Nonoperating items

(¥bn)	FY08	FY09	Diff.
Interest income	0.6	0.7	+0.0
Dividend income	1.2	0.9	-0.2
Other income	1.6	1.1	-0.5
Nonoperating revenues total	3.4	2.7	-0.7
Interest expense	10.5	5.8	-4.7
Equity in losses of unconsolidated subsidiaries and affiliates	8.0	3.4	-4.7
Foreign exchange loss	0.9	1.0	+0.1
Other expenses	4.6	3.9	-0.7
Nonoperating expenses total	24.1	14.0	-10.0
Nonoperating items total	-20.6	-11.4	+9.3

◆ Extraordinary items

(¥bn)	FY08	FY09	Diff.
Gain on sales of property, plant and equipment	1.3	1.0	-0.3
Gain on sales of investment securities	0.2	7.2	+7.0
Gain on prior term adjustments	0.4	-	-0.4
Others	0.2	1.2	+1.0
Extraordinary income total	2.1	9.5	+7.4
Loss on disposal and sales of fixed assets	2.4	1.5	-0.9
Write-down of investment securities	2.7	1.2	-1.5
Special factory operating loss	10.2	10.7	+0.5
Loss on impairment	11.6	4.4	-7.2
Restructuring costs	3.3	20.6	+17.3
Additional contribution to reserve for losses on securities held in money trusts	-	7.2	+7.2
Others	3.1	2.5	-0.6
Extraordinary losses total	33.3	48.2	+14.8
Extraordinary items total	-31.2	-38.7	-7.5

Note: For more information, see the Financial Statements-Summary for the year ended March 31, 2010.

◆ Consolidated Statements of Cash Flows

	(¥bn)	FY08	FY09	Diff.
Income before income taxes		-33.9	-36.6	-2.7
Depreciation and amortization		67.4	61.9	-5.5
Loss on impairment		11.6	4.4	-7.2
Increase or Decrease in inventories		-4.4	29.6	+34.0
Income taxes paid		-11.3	-4.0	+7.2
Increase or Decrease in receivables & payables		-1.1	8.2	+9.3
Others		12.1	16.9	-4.8
Net cash and cash equivalents provided by operating activities		40.4	80.4	+40.0
Purchase of property, plant and equipment		-75.8	-34.1	+41.7
Purchase of investment securities		-3.8	-1.2	+2.6
Purchase of shares of newly consolidated subsidiaries		-24.5	-	+24.5
Others		-12.1	1.9	+14.0
Net cash and cash equivalents used in investing activities		-116.3	-33.4	+82.9
Free Cash Flow		-75.9	47.0	+122.9
Net cash and cash equivalents provided by financing activities, etc		77.2	-42.9	-120.1
Net increase in cash and cash equivalents		1.3	4.1	+2.9

Note: For more information, see the Financial Statements-Summary for the year ended March 31, 2010.

◆ Quarterly Consolidated Statements of Income (fourth quarter)

	FY08 4Q		FY09 4Q		Diff.	
	Amount	% of total	Amount	% of total	Amount	%
Net Sales	205.6	100.0%	205.6	100.0%	-0.0	-0.0%
Cost of sales	162.5	79.0%	157.5	76.6%	-5.0	-3.1%
Gross profit	43.1	21.0%	48.1	23.4%	+4.9	+11.5%
SG & A	47.5	23.1%	46.0	22.4%	-1.5	-3.1%
Operating income	-4.3	-	2.1	1.0%	+6.4	-
Nonoperating items (net)	-5.1	-	-2.1	-	+3.0	-
(Balance of financial expenses)	-2.5	-	-0.9	-	+1.6	-
(Equity on gains and losses of unconsolidated subsidiaries and affiliates)	-1.5	-	0.2	0.1%	+1.7	-
Ordinary income	-9.5	-	-0.1	-	+9.4	-
Extraordinary items(net)	-18.1	-	0.3	0.2%	+18.4	-
Income before income taxes	-27.6	-	0.3	0.1%	+27.8	-
Income taxes	1.3	0.6%	4.0	1.9%	+2.6	+199.4%
Minority interest (net)	-0.5	-	0.5	0.2%	+1.0	-
Net income	-28.4	-	-4.2	-	+24.2	-

Note: For more information, see the Financial Statements-Summary for the year ended March 31, 2010.

◆ Operating Results by Segment (Comparison with FY08 4Q)

(¥bn)	Sales				Operating income			
	FY08 4Q	FY09 4Q	Diff.	%	FY08 4Q	FY09 4Q	Diff.	%
Synthetic Fibers	50.9	57.1	+6.2	+12.2%	-6.9	-4.4	+2.5	-
Films & Plastics	50.6	49.4	-1.3	-2.5%	-5.0	3.0	+8.0	-
Pharma. & H.H.C.	34.0	31.2	-2.8	-8.1%	6.5	4.1	-2.4	-37.4%
Trading & Retail	55.1	54.0	-1.1	-1.9%	0.6	0.9	+0.2	+39.2%
IT & New Products, etc.	15.0	13.9	-1.2	-7.9%	2.8	1.4	-1.3	-48.7%
Elimination & corporate	-	-	-	-	-2.3	-2.9	-0.5	-
Total	205.6	205.6	-0.0	-0.0%	-4.3	2.1	+6.4	-

◆ Consolidated Statements of Income

	(¥bn)	FY08				FY09			
		1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
Net Sales		236.6	253.2	247.9	205.6	166.0	194.2	200.1	205.6
Cost of sales		178.9	195.9	187.5	162.5	124.1	145.1	147.3	157.5
Gross profit		57.8	57.3	60.4	43.1	41.9	49.1	52.8	48.1
SG & A		49.1	50.9	53.2	47.5	43.5	44.8	44.2	46.0
Operating income		8.6	6.4	7.2	-4.3	-1.5	4.3	8.6	2.1
Nonoperating items (net)		-2.0	-4.2	-9.4	-5.1	-2.9	-3.5	-2.8	-2.1
(Balance of financial expenses)		-1.6	-2.3	-2.3	-2.5	-1.0	-1.2	-1.1	-0.9
(Equity on gains and losses of unconsolidated subsidiaries and affiliates)		-1.1	-0.4	-5.0	-1.5	-1.6	-1.0	-1.0	0.2
Ordinary income		6.6	2.3	-2.1	-9.5	-4.4	0.8	5.8	-0.1
Extraordinary items(net)		-0.6	-2.3	-10.2	-18.1	-15.9	-5.7	-17.5	0.3
Income before income taxes		6.0	0.0	-12.4	-27.6	-20.3	-4.8	-11.7	0.3
Income taxes		3.3	2.4	3.2	1.3	-2.6	3.0	-6.0	4.0
Minority interest (net)		0.0	-0.1	-0.6	-0.5	-0.0	0.2	-0.0	0.5
Net income		2.7	-2.3	-15.0	-28.4	-17.7	-8.1	-5.7	-4.2

◆ Nonoperating items

(¥bn)	FY08				FY09			
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
Interest income	0.1	0.1	0.2	0.1	0.3	0.2	0.2	0.0
Dividend income	0.7	0.1	0.4	0.1	0.5	0.1	0.3	0.1
Foreign exchange gain	1.4	-	-	-	0.1	-	-	-
Other income	0.3	0.5	0.4	0.4	0.2	0.6	0.1	0.2
Nonoperating revenues total	2.5	0.7	1.1	0.6	1.2	0.8	0.6	0.3
Interest expense	2.4	2.5	2.9	2.7	1.8	1.5	1.6	1.0
Equity in losses of unconsolidated subsidiaries and affiliates	1.1	0.4	5.0	1.5	1.6	1.0	1.0	-0.2
Foreign exchange loss	-	0.7	1.2	0.4	-	0.8	0.2	0.1
Other expenses	1.0	1.3	1.3	1.1	0.7	1.0	0.6	1.6
Nonoperating expenses total	4.5	4.9	10.4	5.7	4.1	4.3	3.4	2.4
Nonoperating items total	-2.0	-4.2	-9.4	-5.1	-2.9	-3.5	-2.8	-2.1

◆ Extraordinary items

(¥bn)	FY08				FY09			
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
Gain on sales of property, plant and equipment	-	-	-	1.2	1.0	0.0	-	0.0
Gain on sales of investment securities	-	0.0	0.2	-	-	-	1.5	5.8
Others	0.4	0.1	0.1	0.1	0.1	0.1	0.1	0.9
Extraordinary income total	0.4	0.1	0.3	1.3	1.1	0.1	1.6	6.6
Loss on disposal and sales of fixed assets	0.2	0.6	0.6	1.0	0.1	0.3	0.3	0.8
Special factory operating loss	0.5	0.7	1.2	7.7	5.3	2.9	1.1	1.4
Loss on impairment	0.1	0.3	5.8	5.5	0.6	1.6	0.8	1.5
Restructuring costs	-	-	-	3.3	3.2	-	16.2	1.2
Additional contribution to reserve for losses on securities held in money trusts	-	-	-	-	7.2	-	-	-
Others	0.2	0.7	3.0	1.9	0.5	1.0	0.8	1.4
Extraordinary losses total	1.0	2.3	10.5	19.4	17.0	5.8	19.1	6.3
Extraordinary items total	-0.6	-2.3	-10.2	-18.1	-15.9	-5.7	-17.5	0.3

◆ Sales of Principal Pharmaceuticals

(¥bn)

Product	Indication	FY08					FY09				
		1Q	2Q	3Q	4Q	total	1Q	2Q	3Q	4Q	total
<i>Bonalon</i>	Osteoporosis	5.1	4.7	5.8	4.3	19.9	5.4	5.3	6.0	4.6	21.3
<i>Onealfa</i>	Osteoporosis	2.9	2.9	3.4	2.6	11.8	3.1	3.0	3.4	2.4	11.9
Osteoporosis total		8.0	7.7	9.2	6.8	31.7	8.5	8.3	9.5	7.0	33.3
<i>Mucosolvan</i>	Expectorant	2.6	2.2	3.3	2.5	10.5	2.6	2.3	3.2	2.2	10.3
<i>Venilon</i>	Severe infection	2.1	2.0	2.4	1.6	8.2	2.1	1.9	2.2	1.7	8.0
<i>Laxoberon</i>	Laxative	1.2	1.2	1.3	1.1	4.7	1.2	1.2	1.3	1.0	4.7

Bonalon® is the registered trademark of Merck & Co., Inc., Whitehouse Station, NJ, USA.

◆ Development Status of New Pharmaceutical Candidates

(As of March 31, 2010)

Filed

Code no. (Generic name)	Target disease	Medicinal properties/Characteristics	Dosage form	Remarks
TMX-67 (febuxostat)	Gout and hyperuricemia	Xanthine oxidase (XOD) inhibitor	Oral	Developed in-house; refiled in Japan in December 2009
BTR-15K (ciclesonide)	Asthma	Inhaled steroid	Inhaled	Licensed in from Nycomed Group (Switzerland) (New indication: asthma in children)

Phase III

Code no. (Generic name)	Target disease	Medicinal properties/Characteristics	Dosage form	Remarks
GGs (freeze-dried sulfonated human normal immunoglobulin)	Multiple sclerosis	Human immunoglobulin	Injection	Developed jointly with Kaketsuken (New indication)
GTH-42V	Osteoporosis	Alendronate	Injection	Licensed in from Merck & Co., Inc. (USA)
ITM-014 (lanreotide acetate)	Acromegaly	Sustained-release formulation of somatostatin analog	Injection	Licensed in from Beaufour Ipsen S.A. (France)
TV-02H	Psoriasis vulgaris	Active vitamin D ₃	Topical ointment	Conducting trials to obtain approval to import into the PRC

Phase II

Code no. (Generic name)	Target disease	Medicinal properties/Characteristics	Dosage form	Remarks
ITM-077	Type II diabetes	Human glucagon-like peptide-1 analog	Injection	Licensed in from Beaufour Ipsen (France); Developed jointly with Chugai Pharmaceutical Co., Ltd.
NTC-801	Atrial fibrillation and flutter	Selective anti-arrhythmia agent	Oral	Developed jointly with Nissan Chemical Industries, Ltd.

Phase I

Code no. (Generic name)	Target disease	Medicinal properties/Characteristics	Dosage form	Remarks
ITM-058	Osteoporosis	Human PTHrP analog	Injection	Licensed in from Beaufour Ipsen (France)

◆ Development Status by Therapeutic Area

(As of Mar. 31, 2010)

Area	Phase of Clinical Trials				
	Phase I	Phase II	Phase III	Filed	Approved/New Launch
Bone and joint disease	ITM-058		GTH-42V		
Respiratory disease				BTR-15K ^{*5} (New indication: asthma in children)	
Cardio-vascular and metabolic disease		ITM-077 ^{*1} NTC-801 ^{*2}	ITM-014 ^{*3}	TMX-67 ^{*6}	
Other			GGS <i>Venilon</i> ® (New indication for multiple sclerosis) TV-02H ^{*4} (<i>Bonalfa</i> ® Ointment) (PRC)		GGS ^{*7} <i>Venilon</i> ® (New indication for Churg–Strauss Syndrome)

*1 ITM-077 entered Phase II clinical trials in April 2009.

*2 NTC-801 entered Phase II clinical trials in April 2009.

*3 ITM-014 entered Phase III clinical trials in September 2009.

*4 TV-02H entered Phase III clinical trials in the PRC in April 2009.

*5 In March 2010, Teijin filed for a new indication for BTR-15K.

*6 Teijin refiled TMX-67 in Japan in December 2009.

*7 In January 2010, GGS was approved for a new indication (treatment of Churg–Strauss syndrome)

◆ Status of Licensed-in Products in Preclinical Stage (Information for the past three years)

Contract	Company	Description
March 2008	Dong Wha Pharmaceutical Industrial Co., Ltd. (ROK)	Licensing agreement for osteoporosis drug

TEIJIN*Human Chemistry, Human Solutions*

Human Chemistry, Human Solutions

The promise of the Teijin brand is summed up in the resonant statement: "Human Chemistry, Human Solutions".

Our promise is to continue to develop chemical technologies that are friendly to both people and the global environment. It is to keep providing solutions that deliver the real value that society and our customers expect.

We will certainly keep this promise. Constantly working to enhance the Quality of Life –our very reason for being as a company– the Teijin Group will continue to win the trust of society and our customers.